The encapsulation of irinotecan into lipid bilayer-coated mesoporous silica nanoparticles (silicasome) led to an improvement of the delivery and therapeutic efficacy both in vitro and in vivo in KRAS-induced pancreatic cancer cell models. This evidence concerns the gene KRAS and familial pancreatic carcinoma.